8-K: Nuo Therapeutics Secures $1.6M Loan with Warrants

Nuo Therapeutics, Inc. has entered into a Loan and Security Agreement for up to $1.6 million, accompanied by significant warrant issuances and high interest rates, to fund general working capital.

Summary

• Nuo Therapeutics, Inc. secured a Loan and Security Agreement for an aggregate principal amount of up to $1.6 million.
• The initial funding of $1.0 million closed on January 23, 2026, with an additional $600,000 available for a second funding by September 30, 2026, subject to company request and closing conditions.
• The loan proceeds are intended for general working capital purposes.
• The notes bear an initial annual interest rate of 10%, increasing to 12% if the second funding occurs. The second funding notes will bear 12% interest.
• Interest on the notes is payable in Interest Warrants, not cash, at the maturity date of December 31, 2028, or upon earlier prepayment.
• Principal repayment begins March 31, 2027, in eight equal quarterly installments, with an interest-only period through December 31, 2026.
• The loan is secured by a first-priority lien and security interest on all of the company's assets, including intellectual property.
• The company issued various warrants to lenders, all with an exercise price of $1.50 per share and an expiration date of January 23, 2031.
• Warrants issued include Commitment Warrants (8,000 shares aggregate), Origination Initial Warrants (6,667 shares aggregate), and Capital Initial Warrants (133,333 shares aggregate), all immediately exercisable.
• Conditional warrants include Origination Second Warrants (5,000 shares aggregate) and Capital Second Warrants (100,000 shares aggregate), vesting upon the second funding.
• Prepayment Warrants (up to 29,332 shares aggregate) vest upon voluntary or mandatory prepayment events, with fees ranging from 1.5% to 2.75% of the outstanding principal.
• Interest Warrants (up to 226,000 shares aggregate) are issuable at maturity or earlier prepayment for accrued interest.
• The total potential shares issuable from all warrants could reach approximately 508,332 shares.
• The warrants and underlying common stock were offered and sold under a Section 4(a)(2) exemption from registration under the Securities Act, requiring lenders to be accredited investors.

Sentiment

Score: 3

Explanation: While securing funding is positive for liquidity, the terms of the loan (high interest rates, payment of interest in warrants, significant warrant coverage, and a lien on all assets) are quite onerous. This suggests the company is in a challenging financial position and had to accept unfavorable terms, leading to substantial future dilution for shareholders. The involvement of insiders as major lenders further underscores potential difficulties in attracting external capital on better terms.

Positives

• Secured up to $1.6 million in financing, providing necessary working capital for operations.
• The loan includes a second funding tranche of $600,000, offering additional capital flexibility if needed.
• The interest-only period until December 31, 2026, provides immediate cash flow relief for the company.

Negatives

• High annual interest rates of 10% to 12% indicate a high cost of capital, suggesting limited access to traditional financing.
• Interest payments are made in warrants (Interest Warrants), leading to significant potential dilution for existing shareholders.
• The loan is secured by a first-priority lien on all company assets, including intellectual property, which is a substantial encumbrance.
• Significant warrant coverage (20-25% of loan amounts, plus commitment, origination, and interest warrants) will result in substantial dilution upon exercise.
• Prepayment fees of up to 2.75% are payable in warrants, adding to potential dilution even if the loan is repaid early.
• The common stock is currently only eligible for the OTCQB Venture Market, with no assurance of listing on a higher tier or national exchange, which could limit liquidity for warrant holders.

Risks

• Significant dilution risk for existing shareholders due to the issuance of various warrants (Commitment, Origination, Capital, Prepayment, and Interest Warrants) at an exercise price of $1.50 per share.
• The company's assets, including intellectual property, are pledged as collateral, increasing financial risk in case of default.
• The company's ability to request the $600,000 second funding is subject to closing conditions, meaning the full $1.6 million is not guaranteed.
• The common stock's eligibility only on the OTCQB Venture Market may limit liquidity and increase volatility for investors.
• The company's reliance on related parties (Board member, significant beneficial owners) for a substantial portion of the loan may indicate challenges in securing external, arms-length financing.

Future Outlook

The company intends to use the funding proceeds for general working capital purposes. No specific forward-looking statements regarding operational performance or growth targets were provided beyond the financing details.

Management Comments

• David E. Jorden, Chief Executive and Financial Officer, signed the Loan and Security Agreement and the 8-K filing on behalf of Nuo Therapeutics, Inc.

Industry Context

This financing event suggests Nuo Therapeutics, Inc. is seeking capital to support its ongoing operations, likely reflecting a need for liquidity common among smaller biotechnology or medical device companies. The terms, including high interest rates and substantial warrant coverage, are indicative of a company that may have limited access to more conventional, lower-cost financing options, often seen in early-stage or financially constrained firms within the healthcare sector. The involvement of insiders as significant lenders points to internal support but also potentially a lack of broader market interest in more favorable terms.

Comparison to Industry Standards

• The 10-12% interest rate is significantly higher than typical commercial bank loans for established, profitable companies, aligning more with rates seen in venture debt or distressed financing for companies with higher risk profiles.
• The extensive warrant coverage (Commitment, Origination, Capital, Prepayment, and Interest Warrants, totaling over 500,000 potential shares) is substantial, indicating a significant equity component demanded by lenders, which is common in high-risk, growth-oriented sectors like biotech where traditional debt is scarce.
• Payment of interest and prepayment fees in warrants rather than cash is an aggressive financing structure, often employed by companies looking to preserve cash, but it comes at the cost of significant future shareholder dilution.
• The first-priority lien on all company assets, including intellectual property, is a strong security measure for lenders, typical for companies with limited tangible assets or a higher perceived risk of default, contrasting with less restrictive covenants in more mature company financings.

Corporate Governance

Related Party Transactions

• Scott M. Pittman, a member of the Board of Directors and a more than 10% beneficial owner of the company's common stock, loaned $200,000 in the Initial Funding and committed to loaning $210,000 in a Second Funding. He was issued Commitment, Origination Initial, Capital Initial, Origination Second, Capital Second, Prepayment, and Interest Warrants.
• Paul Anthony Jacobs, a more than 5% beneficial owner of the company's common stock, loaned $300,000 in the Initial Funding. He was issued Commitment, Origination Initial, Capital Initial, Prepayment, and Interest Warrants.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the various warrants issued to lenders, especially the Interest Warrants and Capital Warrants. The high cost of debt and asset lien could also negatively impact shareholder value.
• **Lenders**: Benefit from high interest rates (10-12%), substantial warrant coverage, and a first-priority security interest on all company assets, providing strong downside protection and potential upside equity participation.
• **Employees**: The funding provides working capital, which helps ensure continued operations and employment, at least in the short to medium term.
• **Creditors**: The first-priority lien on all assets means other unsecured creditors would be subordinate to these lenders in case of liquidation.
• **Customers/Suppliers**: Continued operations supported by the funding may ensure stability in product availability (Aurix) and ongoing business relationships.

Next Steps

• The company may request the $600,000 Second Funding by September 15, 2026, with a potential closing date of September 30, 2026.
• The company will begin making quarterly principal repayments on the Notes starting March 31, 2027.
• The company is obligated to file all required reports under the Exchange Act in a timely manner until the warrants expire or are exercised.

Key Dates

Recommendation

While the financing provides much-needed working capital, the terms are highly dilutive and expensive, reflecting significant financial strain. The high interest rates, payment of interest in warrants, and extensive warrant coverage will likely weigh on future share price performance. The first-priority lien on all assets also increases risk. Without clear evidence of a strong turnaround or significant operational improvements, the stock remains a 'hold' due to the high cost of capital and potential for substantial dilution, offsetting the benefit of secured liquidity.

Keywords

Nuo Therapeutics, Loan Agreement, Secured Promissory Note, Warrants, Capital Raise, Dilution, Working Capital, SEC Filing, Corporate Finance, OTC Markets, Insider Lending, Asset Lien